FDA — authorised 2 August 2019
- Application: NDA211810
- Marketing authorisation holder: DAIICHI SANKYO INC
- Local brand name: TURALIO
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 TURALIO™ in United States
FDA authorised TURALIO™ on 2 August 2019
Marketing authorisations
FDA
- Status: approved
TURALIO™ in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is TURALIO™ approved in United States?
Yes. FDA authorised it on 2 August 2019; FDA has authorised it.
Who is the marketing authorisation holder for TURALIO™ in United States?
DAIICHI SANKYO INC holds the US marketing authorisation.